Interferons and bladder cancer.
Urol Clin North Am
; 27(1): 171-8, xi, 2000 Feb.
Article
em En
| MEDLINE
| ID: mdl-10696256
ABSTRACT
With the introduction of BCG, intravesical instillation of immunotherapeutic agents has become a mainstay of therapy in the treatment of superficial bladder cancer. Interferon is capable of inducing a non-specific cellular and humoral immune response towards tumor cells. It has shown promise in reducing the recurrence and progression rates of superficial bladder cancer. In contrast to BCG, intravesical interferon is associated with minimal side effects and a very low dropout rate. Current research has focused on the use of interferon in combination with immunotherapeutic and cytotoxic drugs.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Interferons
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Urol Clin North Am
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Estados Unidos